Vertex Pharmaceuticals Inc (VRTX) - Total Assets
Based on the latest financial reports, Vertex Pharmaceuticals Inc (VRTX) holds total assets worth $25.64 Billion USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See VRTX total equity for net asset value and shareholders' equity analysis.
Vertex Pharmaceuticals Inc - Total Assets Trend (1990–2025)
This chart illustrates how Vertex Pharmaceuticals Inc's total assets have evolved over time, based on quarterly financial data.
Vertex Pharmaceuticals Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Vertex Pharmaceuticals Inc's total assets of $25.64 Billion consist of 43.7% current assets and 56.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 19.8% |
| Accounts Receivable | $2.05 Billion | 8.0% |
| Inventory | $1.69 Billion | 6.6% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $424.20 Million | 1.7% |
| Goodwill | $1.09 Billion | 4.2% |
Asset Composition Trend (1990–2025)
This chart illustrates how Vertex Pharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Vertex Pharmaceuticals Inc market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Vertex Pharmaceuticals Inc's current assets represent 43.7% of total assets in 2025, a decrease from 50.0% in 1990.
- Cash Position: Cash and equivalents constituted 19.8% of total assets in 2025, down from 47.8% in 1990.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 5.0% of total assets, an increase from 0.0% in 1990.
- Asset Diversification: The largest asset category is accounts receivable at 8.0% of total assets.
Vertex Pharmaceuticals Inc Competitors by Total Assets
Key competitors of Vertex Pharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Argen-X
F:1AE
|
Germany | €7.18 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229
|
China | CN¥3.06 Billion |
|
R&G PharmaStudies Co. Ltd. A
SHE:301333
|
China | CN¥2.31 Billion |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
|
China | CN¥819.45 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.16 Billion |
Vertex Pharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.90 | 2.69 | 4.39 |
| Quick Ratio | 2.46 | 2.35 | 4.24 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $7.34 Billion | $6.03 Billion | $6.60 Billion |
Vertex Pharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between Vertex Pharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 6.68 |
| Latest Market Cap to Assets Ratio | 4.19 |
| Asset Growth Rate (YoY) | 13.8% |
| Total Assets | $25.64 Billion |
| Market Capitalization | $107.56 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Vertex Pharmaceuticals Inc's assets at a significant premium (4.19x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Vertex Pharmaceuticals Inc's assets grew by 13.8% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Vertex Pharmaceuticals Inc (1990–2025)
The table below shows the annual total assets of Vertex Pharmaceuticals Inc from 1990 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $25.64 Billion | +13.80% |
| 2024-12-31 | $22.53 Billion | -0.87% |
| 2023-12-31 | $22.73 Billion | +25.23% |
| 2022-12-31 | $18.15 Billion | +35.13% |
| 2021-12-31 | $13.43 Billion | +14.30% |
| 2020-12-31 | $11.75 Billion | +41.27% |
| 2019-12-31 | $8.32 Billion | +33.18% |
| 2018-12-31 | $6.25 Billion | +76.14% |
| 2017-12-31 | $3.55 Billion | +22.54% |
| 2016-12-31 | $2.89 Billion | +15.89% |
| 2015-12-31 | $2.50 Billion | +6.88% |
| 2014-12-31 | $2.34 Billion | +0.74% |
| 2013-12-31 | $2.32 Billion | -15.96% |
| 2012-12-31 | $2.76 Billion | +25.18% |
| 2011-12-31 | $2.20 Billion | +27.75% |
| 2010-12-31 | $1.73 Billion | -11.76% |
| 2009-12-31 | $1.96 Billion | +99.44% |
| 2008-12-31 | $980.48 Million | +63.01% |
| 2007-12-31 | $601.48 Million | -34.73% |
| 2006-12-31 | $921.58 Million | +67.87% |
| 2005-12-31 | $549.00 Million | +0.65% |
| 2004-12-31 | $545.45 Million | -24.70% |
| 2003-12-31 | $724.41 Million | -11.19% |
| 2002-12-31 | $815.72 Million | -11.83% |
| 2001-12-31 | $925.13 Million | +19.70% |
| 2000-12-31 | $772.88 Million | +232.56% |
| 1999-12-31 | $232.40 Million | -12.73% |
| 1998-12-31 | $266.30 Million | -9.91% |
| 1997-12-31 | $295.60 Million | +105.99% |
| 1996-12-31 | $143.50 Million | +44.95% |
| 1995-12-31 | $99.00 Million | -14.80% |
| 1994-12-31 | $116.20 Million | +90.49% |
| 1993-12-31 | $61.00 Million | +19.61% |
| 1992-12-31 | $51.00 Million | -10.68% |
| 1991-12-31 | $57.10 Million | +520.65% |
| 1990-12-31 | $9.20 Million | -- |
About Vertex Pharmaceuticals Inc
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age a… Read more